Mouse Anti-CFH Recombinant Antibody (CBXF-0114) (CBMAB-F2653-CQ)


Basic Information
Application | Note |
WB | 1:100-1:1,000 |
IP | 1-2 µg per 100-500 µg of total protein (1 ml of cell lysate) |
IF(ICC) | 1:50-1:500 |
IHC-P | 1:50-1:500 |
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
Accelerates the decay of the complement alternative pathway (AP) C3 convertase C3bBb, thus preventing local formation of more C3b, the central player of the complement amplification loop (PubMed:19503104).
As a cofactor of the serine protease factor I, CFH also regulates proteolytic degradation of already-deposited C3b (PubMed:18252712, PubMed:28671664).
In addition, mediates several cellular responses through interaction with specific receptors. For example, interacts with CR3/ITGAM receptor and thereby mediates the adhesion of human neutrophils to different pathogens. In turn, these pathogens are phagocytosed and destroyed (PubMed:9558116, PubMed:20008295).
Complement activation, alternative pathway Source: UniProtKB-KW
Regulation of complement activation Source: MGI
Regulation of complement-dependent cytotoxicity Source: MGI
Viral process Source: UniProtKB-KW
Complement factor H deficiency (CFHD): A disorder that can manifest as several different phenotypes, including asymptomatic, recurrent bacterial infections, and renal failure. Laboratory features usually include decreased serum levels of factor H, complement component C3, and a decrease in other terminal complement components, indicating activation of the alternative complement pathway. It is associated with a number of renal diseases with variable clinical presentation and progression, including membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome.
Hemolytic uremic syndrome atypical 1 (AHUS1): An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.
Macular degeneration, age-related, 4 (ARMD4): A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Related Products
Rabbit Anti-CFH Recombinant Antibody (CBXF-1227) (CAT#: CBMAB-F0754-CQ)
Mouse Anti-CFH Recombinant Antibody (CBXF-1415) (CAT#: CBMAB-F4002-CQ)
Mouse Anti-CFH Recombinant Antibody (CBXF-0113) (CAT#: CBMAB-F2652-CQ)
Mouse Anti-CFH Recombinant Antibody (CBFYC-1758) (CAT#: CBMAB-C1820-FY)
Rabbit Anti-CFH Recombinant Antibody (CBXF-1226) (CAT#: CBMAB-F0755-CQ)
Mouse Anti-CFH Recombinant Antibody (CBXF-1416) (CAT#: CBMAB-F4003-CQ)
Mouse Anti-CFH Recombinant Antibody (CBXF-1909) (CAT#: CBMAB-F1611-CQ)
Mouse Anti-CFH Recombinant Antibody (CBXF-3677) (CAT#: CBMAB-F1036-CQ)
Mouse Anti-CFH Recombinant Antibody (CBXF-2743) (CAT#: CBMAB-F3460-CQ)
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
